A detailed history of Bowen Hanes & CO Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Bowen Hanes & CO Inc holds 13,635 shares of ABBV stock, worth $2.33 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
13,635
Previous 10,150 34.33%
Holding current value
$2.33 Million
Previous $1.74 Million 54.71%
% of portfolio
0.07%
Previous 0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $570,982 - $694,665
3,485 Added 34.33%
13,635 $2.69 Million
Q2 2024

Aug 12, 2024

SELL
$154.79 - $180.76 $1.07 Million - $1.24 Million
-6,885 Reduced 40.42%
10,150 $1.74 Million
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $2.15 Million - $2.45 Million
13,470 Added 377.84%
17,035 $3.1 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $4,637 - $5,771
-35 Reduced 0.97%
3,565 $480,000
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $125,810 - $144,889
870 Added 31.87%
3,600 $573,000
Q2 2022

Aug 12, 2022

BUY
$137.62 - $174.96 $4,816 - $6,123
35 Added 1.3%
2,730 $418,000
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $51,072 - $57,974
480 Added 21.67%
2,695 $291,000
Q1 2021

May 13, 2021

BUY
$102.3 - $112.62 $226,594 - $249,453
2,215 New
2,215 $240,000
Q2 2019

Aug 13, 2019

SELL
$65.7 - $83.98 $202,684 - $259,078
-3,085 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$77.14 - $90.79 $493,696 - $581,056
-6,400 Reduced 67.47%
3,085 $249,000
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $738,407 - $910,654
9,485 New
9,485 $874,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $302B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bowen Hanes & CO Inc Portfolio

Follow Bowen Hanes & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bowen Hanes & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bowen Hanes & CO Inc with notifications on news.